Leading Global Multiple Sclerosis Research Center Taps IBM Analytics to Improve Patient Care

ARMONK, N.Y., April 26, 2012 /PRNewswire/ -- IBM (NYSE: IBM) today announced that researchers from The State University of New York (SUNY) at Buffalo are using IBM analytics technology to study more than 2,000 genetic and environmental factors that may contribute to multiple sclerosis (MS) symptoms.

(Logo: http://photos.prnewswire.com/prnh/20090416/IBMLOGO)

As part of the initiative, Researchers will tap into IBM's analytics technology to develop algorithms for big data containing genomic datasets to uncover critical factors that speed up disease progression in MS patients. Insights gained from the research will be shared with hundreds of doctors to better tailor individual treatments to slow brain injury, physical disability and cognitive impairments caused by MS.

Using IBM analytics technology, SUNY Buffalo researchers can for the first time explore clinical and patient data to find hidden trends among MS patients by looking at factors such as gender, geography, ethnicity, diet, exercise, sun exposure, and living and working conditions. The big data including medical records, lab results, MRI scans and patient surveys, arrives in various formats and sizes, requiring researchers to spend days making it manageable before they can analyze it.

Using an IBM Netezza analytics appliance with software from IBM business partner, Revolution Analytics, researchers can now analyze all the disparate data in a matter of minutes instead of days, regardless of what type or size it is. The technology automatically consumes and analyzes the data, and makes the results available for further analysis. As a result, researchers can now focus their time on analyzing trends instead of managing data.

MS is a chronic neurological disease for which there is no cure. The disease is believed to be caused by a combination of genetic, environmental, infectious and autoimmune factors making treatment difficult. According to the National Multiple Sclerosis Society, there are approximately 400,000 people in the US with MS, and 200 people are diagnosed every week. Worldwide, MS is estimated to affect more than 2.1 million people.

"Multiple Sclerosis is a debilitating and complex disease whose cause is unknown. No two people share the exact same symptoms, and individual symptoms can worsen unexpectedly," said Dr. Murali Ramanathan, Lead Researcher at SUNY Buffalo. "Identifying common trends across massive amounts of MS data is a monumental task that is much like trying to shoot a speeding bullet out of the sky with another bullet. IBM analytics helps our researchers fine tune their aim and match the speed of analysis with the rate of data coming into our systems. Our goal is to demystify why the disease progresses more rapidly in some patients and get those insights back to other researchers, so they can find new treatments."

Since 2007, SUNY Buffalo researchers have been at the forefront of studying clinical and historical data from MS patients to identify genetic and environmental factors that contribute to the risk of developing the disease. These researchers are studying different age groups to see why the disease appears early in some children and why people who are diagnosed later in life tend to have a more aggressive course that affects their ability to walk. They are also looking at why MS is more common in northern latitudes and less common towards the equator, calling into question the role sunlight or lack thereof plays in the disease.

"Organizations that glean insights from big data and apply them to pervasive diseases like MS have the potential to greatly change the way patients receive treatment," said Dan Pelino, general manager, healthcare and life sciences at IBM. "The work that SUNY Buffalo is doing is a prime example of how IBM clients are literally changing the world with big data analytics, from advancing medical research, to generating clean energy and giving consumers what they want before they know they want it."

IBM Netezza appliances are optimized systems based on IBM BladeCenter technology that can analyze petabytes of data significantly faster than competing options, and at a much lower total cost of ownership. Unlike competing appliances, Netezza can be up and running in minutes instead of days or weeks.

Read more:
Leading Global Multiple Sclerosis Research Center Taps IBM Analytics to Improve Patient Care

Preliminary Data Suggest Spasticity May Be Reduced in Relapsing-Remitting Multiple Sclerosis Patients Who Transitioned …

JERUSALEM--(BUSINESS WIRE)--

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA - News) today announced interim data from a prospective, open label survey study evaluating spasticity in patients with relapsing-remitting multiple sclerosis (RRMS) who transitioned to COPAXONE (glatiramer acetate injection) from interferon-beta treatment. These data were presented today at the 64th Annual Meeting of the American Academy of Neurology (AAN) in New Orleans, Louisiana.

Interim results for the first 52 of 110 participants revealed a significant reduction in muscle stiffness, pain and discomfort, as well as the effect of spasticity on the ability to walk, body movements and activities of daily living (ADLs). Improvement was also found in reduction of total spasticity scores during the six month period.

Spasticity, one of the more common symptoms of RRMS, can often negatively impact patients daily lives, said Cira Fraser PhD, RN, ACNS-BC, Associate Professor and Graduate Faculty, Marjorie K. Unterberg School of Nursing and Health Studies, Monmouth University, West Long Branch, New Jersey and Principal Investigator of the study. These data may suggest a reduction in the key measures of spasticity in RRMS patients who discontinued interferon-beta treatment and transitioned to COPAXONE.

The prospective longitudinal survey research study is evaluating 110 participants utilizing the Multiple Sclerosis Spasticity Scale (MSSS-88), the Performance Scales, and a socio demographic questionnaire completed when transitioning between treatments and at month six. Study criteria included participants who had stopped interferon-beta treatment within 30 days; were about to start, or started COPAXONE within the previous 21 days; had spasticity; and were able to ambulate with unilateral support or without. Of the 52 participants, whose data are currently being reported, 35 percent were taking medication for spasticity prior to enrollment and during the six month period.

These study results contribute to the body of knowledge on the treatment of RRMS, said Jon Congleton, Teva's Senior Vice President, Global Brand Strategic Marketing. Through the ongoing support of research such as this, Teva is continually working to help improve the lives of RRMS patients.

ABOUT THE STUDY

Additional detail can be found on the AAN website: http://www.abstracts2view.com/aan/

[P07.074] A Prospective Study of Spasticity in Individuals with Multiple Sclerosis (MS) in Transition from Interferon-Beta to Glatiramer Acetate (Session P07: Multiple Sclerosis: Symptoms, April 26 at 2:00 PM) Cira J. Fraser, West Long Branch, NJ

ABOUT COPAXONE

Read more from the original source:
Preliminary Data Suggest Spasticity May Be Reduced in Relapsing-Remitting Multiple Sclerosis Patients Who Transitioned ...

Tennis: Game Point on Multiple Sclerosis

I first started to play tennis back in the summer of 2009, when I first heard the name and story of Sue Burke. Sue Burke is not just any tennis player though. Sue was diagnosed with multiple sclerosis just like I was in 2006. The story of Sue Burke is what actually made me start to play sport of tennis.

Sue is a world class tennis coach who coached the American women's team at one of the highest venues in the world. Sue was an American women's Pan American Games coach in Argentina. The fact that she is still active in the sport though is the reason I decided to give tennis a try, and I fell in love with the sport.

This is the reason I will bring you my top ten benefits for playing tennis with multiple sclerosis.

Benefit number one

Tennis is not a sport that requires constant energy like football, basketball, and hockey. This means that I do get short periods of rest in between the speed and agility that playing tennis does require. This allows me to play a complete game on my good days.

Benefit number two

Do to my multiple sclerosis I had a period of time where I was fighting to regain my reflexes, and my reaction times. These are things that my doctor regularly checks up on when I go to my appointments. I have been able to regain both my reflexes and reaction time through the sport of tennis.

Benefit number three

Tennis much like swimming has been responsible for giving me back my balance. The stop and go motions of playing tennis is the reason I can move better today than I could six years ago, when I was first being diagnosed with multiple sclerosis.

Benefit number four

Continue reading here:
Tennis: Game Point on Multiple Sclerosis

Dementia study by Royal Aust College

The Royal Australian and New Zealand College of Psychiatrists' Faculty of Psychiatry of Old Age welcomes the Australian government's announcement of initiatives for people with dementia and services to support aged care, but says more is need for the mental health needs of people in old age.

'Investment in dementia care and diagnosis and improved aged care services are essential and will go some way to improving the lives of older people with mental illness, and those of their families and carers. Improved access to services that support the person in their own home is particularly welcome,' said Dr Roderick McKay, Chair of The Royal Australian and New Zealand College of Psychiatrists' Faculty of Psychiatry of Old Age.

'In the next 20 years the number of Australians over 65 will double, therefore the mental health care of older people is an important part of in the mental health reform agenda. Planning for the mental health needs of older people and access to mental health care is critical to mitigate against poor mental health outcomes,' said Dr McKay

'Focus on this important area is welcomed, and needs to be built upon so that there is comprehensive support for the mental health of older people. As Minister for Mental Health and Ageing, as well as Social Inclusion, Minister Butler would appear to have an almost unique opportunity to achieve this,' said Dr McKay.

'Older people need to be included in all mental health planning to improve their quality of care, remove discrimination and obtain better understanding of the mental health needs of older Australians. It is vital these issues be considered in the government's Ten Year Roadmap for Mental Health Reform,' said Dr McKay.

'Untreated mental illness robs older Australians of their quality of life, physical health and independence at significant cost to individuals, family and community. While there are effective mental health treatments for older people, limited resources can deny them equitable access. Australia owes its older citizens and their families adequate support, respect, and dignity,' said Dr McKay.

'To improve the quality of mental health care for older people we require national benchmarks for the availability and quality of mental health services for older people, and need national principles for providing coordinated care across different services for older Australians with mental illness. Basic mental health training for people working with older Australian is also essential,' said Dr McKay.

For further information Kirrily Johns +61 3 9601 4940

About The Royal Australian and New Zealand College of Psychiatrists The Royal Australian and New Zealand College of Psychiatrists (RANZCP) is the principal organisation representing the medical specialty of psychiatry in Australia and New Zealand and has responsibility for training, examining and awarding the qualification of Fellowship of the College to medical practitioners.

Original post:
Dementia study by Royal Aust College

More dementia treatment available in Ashburton

Hon Jo Goodhew

Associate Minister of Health

26 April 2012 Media Statement More dementia treatment available in Ashburton

More local Mid Canterbury people suffering from dementia will be cared for in their local community following an extension and refurbishment to an aged care hospital unit officially opened today by Associate Health Minister Jo Goodhew.

This community investment adds another 10 bed dementia unit to the existing 12 psychogeriatric and 15 long stay hospital beds already in the Tuarangi resthome and hospital, says Mrs Goodhew.

We are living longer and sadly that also means that the number of older New Zealanders with dementia is increasing.

A loved one living with dementia is a challenge faced by many families, but there is much that we can do. These additional dedicated beds mean that local people with dementia can, if they choose, remain closer to home should they need residential care.

Providing care for individuals with dementia is a growing issue for our country. The 2010 aged residential care services review identified the most pressing need as expanding dementia units, beds and services.

The Government responded last year with an additional $44 million over four years to look after people living with dementia. This includes $40 million for residential dementia services and $4 million for respite care for full-time carers of individuals with dementia.

The Government is committed to ensuring all older people in residential care, including those with dementia, receive quality services and care.

Read the original here:
More dementia treatment available in Ashburton

Dementia alarm bells in Boroondara

FORMER librarian Heather Robertson-Clarke can no longer read or write and is slowly losing her speech.

The Hawthorn East resident knows first-hand the effects of dementia after being diagnosed with the cruel and debilitating disease three years ago.

She is just one of thousands across Boroondara suffering from the affliction.

And the number of Boroondara residents with dementia is expected to skyrocket 170 per cent by 2050, a new study has revealed.

The figures, commissioned by Alzheimers Australia Vic, projected Boroondara residents living with dementia will balloon from 2582 today to more than 6900 in less than 40 years, placing a heavy toll on the districts medical and care services.

Alzheimers Australia Vic chief executive Maree McCabe said the prevalence of dementia would cost the nation $83 billion a year by 2050, which will exceed any other medical condition.

(The figures) really are frightening - its really important we are proactive, Ms McCabe said.

Almost 72,000 Victorians have dementia, which is expected to boom to 246,000 by 2050, according to the study by Deloitte Access Economics.

Prof David Ames, director of Parkvilles National Ageing Research Institute, said statistics revealed there would be as many Victorians with dementia in 2050 as there are Australians presently with the condition.

Ms McCabe said early detection was key.

Read more:
Dementia alarm bells in Boroondara

MULTIMEDIA SPECIAL: Don't forget Yarra Ranges dementia sufferers

>> MULTIMEDIA SPECIAL: Love amid loss as dementia takes hold

FRIGHTENING new statistics reveal the number of residents in the Yarra Ranges with dementia is expected to skyrocket by 298 per cent by 2050.

The figures, commissioned by Alzheimers Australia Vic, project the number of Yarra Ranges residents living with dementia will grow from 1543 to more than 6000 in less than 40 years, placing a heavy toll on the districts medical and care services.

The shock figures come as Caladenia Dementia Care in Mooroolbark campaigns for $1.7 million funding to build a dementia-specific overnight respite centre.

Manager Sarah Yeates said there was an enormous and growing need for the centre.

The care that happens in nursing homes is just not suitable for people with dementia, especially for those in the early stages, Ms Yeates said.

She said they were seeing an increasing demand for their services particularly from younger people, with their youngest patient just 34.

The community has already raised $85,000 for the project, but Ms Yeates said they were continuing to appeal for funding from state and federal governments.

Among those who will benefit from respite care is Coldstreams Gerda and Marty De Clercq (pictured).

Two-and-a-half years ago Mr De Clercq, 68, was diagnosed with dementia and his wife is his sole carer.

Go here to read the rest:
MULTIMEDIA SPECIAL: Don't forget Yarra Ranges dementia sufferers

MULTIMEDIA SPECIAL: Don’t forget Yarra Ranges dementia sufferers

>> MULTIMEDIA SPECIAL: Love amid loss as dementia takes hold

FRIGHTENING new statistics reveal the number of residents in the Yarra Ranges with dementia is expected to skyrocket by 298 per cent by 2050.

The figures, commissioned by Alzheimers Australia Vic, project the number of Yarra Ranges residents living with dementia will grow from 1543 to more than 6000 in less than 40 years, placing a heavy toll on the districts medical and care services.

The shock figures come as Caladenia Dementia Care in Mooroolbark campaigns for $1.7 million funding to build a dementia-specific overnight respite centre.

Manager Sarah Yeates said there was an enormous and growing need for the centre.

The care that happens in nursing homes is just not suitable for people with dementia, especially for those in the early stages, Ms Yeates said.

She said they were seeing an increasing demand for their services particularly from younger people, with their youngest patient just 34.

The community has already raised $85,000 for the project, but Ms Yeates said they were continuing to appeal for funding from state and federal governments.

Among those who will benefit from respite care is Coldstreams Gerda and Marty De Clercq (pictured).

Two-and-a-half years ago Mr De Clercq, 68, was diagnosed with dementia and his wife is his sole carer.

Go here to read the rest:
MULTIMEDIA SPECIAL: Don't forget Yarra Ranges dementia sufferers

Bakewells and dogs vs dementia

26 April 2012 Last updated at 02:44 ET By James Gallagher Health and science reporter, BBC News

The drifting smells of a Bakewell tart, guide dogs for the mind and hi-tech wristbands could all have a future in helping people with dementia.

They are some of the winners of a competition by the Design Council and the Department of Health to develop new ideas in care.

The winners are all prototypes, but the aim is to produce them on a mass scale.

David Cameron has described dementia as a "national crisis" which affects 800,000 people in the UK.

The slow death of the brain in dementia affects memory, language and understanding. One of the problems can be forgetting to eat, which is what one of the design ideas is trying to overcome.

The "Ode" project works on the same principle as smells wafting from the kitchen making you hungry. It pumps fragrances of food into the air to whet the appetite of people who are not eating.

Lizzie Olstrom, who is part of the design team, told the BBC: "So much of appetite is about smell, the sensory anticipation of food. [Ode] uses fragrances to re-awaken appetite."

So far they have used smells of a Bakewell tart, citrus and spices. However, the tempting aroma of fish and chips has not translated so well. "Would you want vinegar and wet paper smells in the house?" she asked.

So far, she said the product had "compelling results" after being tested in homes. However, larger-scale tests will be needed to see if the product really helps people.

See the rest here:
Bakewells and dogs vs dementia

Dementia " the most serious health crisis this century"

Alzheimers New Zealand urges New Zealand government to recognise dementia as the most serious health crisis to be faced this century

Alzheimers New Zealand is encouraged by the Australian federal governments recent announcement that they will be committing almost AUS $270 million to dementia and hopes this announcement will go some way toward influencing our own government to take further financial action in New Zealand.

Under an aged-care reform package the Australian government will spend a total of $269.4 million over five years, including $164.3 million to be paid as supplements to people with dementia living in aged-care facilities and at home. The remainder of the money will go toward promoting early diagnosis of the disease. However, this amount this falls short of calls by Alzheimer's Australia for a $500m investment.

This financial commitment from the Australian government coupled with the recent announcement from the UK government that they will be doubling funding for dementia research, shows how other governments are stepping up and taking action to prepare for the inevitable rise in dementia. Alzheimers New Zealand is now urging our own government to take action and recognise dementia as the most serious health crisis to be faced this century.

A report released this month by the World Health Organisation (WHO) revealed the incidence of dementia is exploding in line with the rapid growth in aging populations worldwide, the most profound socio-economic phenomenon of this century. The number of people living with dementia worldwide, estimated at 35.6 million in 2010, is set to nearly double every 20 years, reaching 65.7 million in 2030 and 115.4 million in 2050.

In New Zealand, dementia is expected to increase to epidemic proportions in the very near future due to our countrys aging population. Today there around 44,000 recorded cases of dementia, however, we expect the true figure to be significantly higher than this as only 60% of people are diagnosed, according to the World Alzheimer Report 2011. Around half of all New Zealanders with dementia live with family carers, many of whom are providing around-the-clock care with little or no government support.

Alzheimers New Zealand is now approaching the third year of its National Dementia Strategy, launched at Parliament in May 2010. The strategy establishes clear actions to better support people with dementia and their carers. The document was developed in consultation with stakeholders throughout the sector, as well as with those who face the daily challenge of living with the disease. The strategy identifies key areas needing investment including early diagnosis and management of the disease, appropriate quality services, better supports for carers who provide in-home care, and development of a skilled work-force.

The success of the National Dementia Strategy hinges on the New Zealand governments recognition of the social and economic impacts of the disease and adopting dementia as a national health priority. While the New Zealand dementia community is working towards fulfilling the action points of the strategy, the New Zealand government is yet to formally adopt it.

The New Zealand government needs to recognise dementia as a national crisis in order to adequately fund the sector and best prepare for the significant costs of dementia in the future.

Last years Budget announcement of $44m to dementia was a step in the right direction but additional funding is needed to support people living with dementia in the home, says Alzheimers New Zealand chairperson, Martin Brooks.

The rest is here:
Dementia " the most serious health crisis this century"

Dementia ” the most serious health crisis this century”

Alzheimers New Zealand urges New Zealand government to recognise dementia as the most serious health crisis to be faced this century

Alzheimers New Zealand is encouraged by the Australian federal governments recent announcement that they will be committing almost AUS $270 million to dementia and hopes this announcement will go some way toward influencing our own government to take further financial action in New Zealand.

Under an aged-care reform package the Australian government will spend a total of $269.4 million over five years, including $164.3 million to be paid as supplements to people with dementia living in aged-care facilities and at home. The remainder of the money will go toward promoting early diagnosis of the disease. However, this amount this falls short of calls by Alzheimer's Australia for a $500m investment.

This financial commitment from the Australian government coupled with the recent announcement from the UK government that they will be doubling funding for dementia research, shows how other governments are stepping up and taking action to prepare for the inevitable rise in dementia. Alzheimers New Zealand is now urging our own government to take action and recognise dementia as the most serious health crisis to be faced this century.

A report released this month by the World Health Organisation (WHO) revealed the incidence of dementia is exploding in line with the rapid growth in aging populations worldwide, the most profound socio-economic phenomenon of this century. The number of people living with dementia worldwide, estimated at 35.6 million in 2010, is set to nearly double every 20 years, reaching 65.7 million in 2030 and 115.4 million in 2050.

In New Zealand, dementia is expected to increase to epidemic proportions in the very near future due to our countrys aging population. Today there around 44,000 recorded cases of dementia, however, we expect the true figure to be significantly higher than this as only 60% of people are diagnosed, according to the World Alzheimer Report 2011. Around half of all New Zealanders with dementia live with family carers, many of whom are providing around-the-clock care with little or no government support.

Alzheimers New Zealand is now approaching the third year of its National Dementia Strategy, launched at Parliament in May 2010. The strategy establishes clear actions to better support people with dementia and their carers. The document was developed in consultation with stakeholders throughout the sector, as well as with those who face the daily challenge of living with the disease. The strategy identifies key areas needing investment including early diagnosis and management of the disease, appropriate quality services, better supports for carers who provide in-home care, and development of a skilled work-force.

The success of the National Dementia Strategy hinges on the New Zealand governments recognition of the social and economic impacts of the disease and adopting dementia as a national health priority. While the New Zealand dementia community is working towards fulfilling the action points of the strategy, the New Zealand government is yet to formally adopt it.

The New Zealand government needs to recognise dementia as a national crisis in order to adequately fund the sector and best prepare for the significant costs of dementia in the future.

Last years Budget announcement of $44m to dementia was a step in the right direction but additional funding is needed to support people living with dementia in the home, says Alzheimers New Zealand chairperson, Martin Brooks.

The rest is here:
Dementia " the most serious health crisis this century"

DEMENTIA CARE: the cost of caring in the west

DEMENTIA will become Australias most expensive medical condition over the next 40 years, with annual costs predicted to balloon from $6 billion this year to about $83 billion by 2050.

Alzheimers Australia Vic chief executive Maree McCabe said aged care for a dementia patient cost about $21,500 each year and would increase exponentially with wages, treatment and interventions.

Governments know what we need, the time has come now to outline a funding plan for it - not for the next year or five years, but for over the next decade to 20 years, Ms McCabe said.

The Federal Government terminated The Dementia Initiative - making dementia a national health priority in its 2011-12 Budget.

Last week, the Federal Government announced $268.4 million over five years to tackle dementia.

This includes $164.3 million for people receiving home care packages and in residential care, and there will also be extra support for primary health care providers.

However this falls short of the $500 million over five years called for by Alzheimers Australia.

We need to increase our services, Ms McCabe said.

We need to raise awareness about dementia, especially when it comes to ensuring people achieve a timely diagnosis.

National Ageing Research Institute director Prof David Ames said huge advances had been made in understanding the biology of dementia, but treatments remained limited.

Here is the original post:
DEMENTIA CARE: the cost of caring in the west

Man arrested or planting mercury at Albany Med faces federal charges

Martin Kimber

ALBANY The man already charged with putting mercury in food and on other places including the heater where it would be vaporized and inhaled in the Albany Medical Center Hospital cafeteria now faces federal charges.

U.S. Attorney Richard Hartunian said Martin S. Kimber, 58, of Ruby, faces charges of illegal disposal of a hazardous waste in a manner posing a danger of death of serious bodily injury to others, a charge more commonly referred to as knowing endangerment, and illegal storage and disposal of a hazardous waste without a permit.

The retired pharmacist was previously arrested by Albany Police, with help from FBI and Department of Health investigators, for tampering with a consumer product in the first degree.

According to the U.S. Attorneys Office, a search of Kimbers Ulster County home found he had 21 guns and literature reflecting a sympathy for domestic terrorism.

The cover page in one book, The Turner Diaries includes the phrase This book contains racist propaganda and The FBI said it was a blueprint for the Oklahoma City Bombing.

Investigators also discovered a Nazi swastika on the wall.

The knowing endangerment charge carries a 15 year maximum jail time and a fine of $250,000 or twice the gross loss to any victim. The storage and disposal of hazardous waste without a permit can lead to a maximum of five years in jail and a fine of $250,000 or twice the gross loss to any victim.

The mercury was found in some of the food in the cafeteria that was eaten by at least one person. That person was treated at the hospitals emergency room.

Follow this link:
Man arrested or planting mercury at Albany Med faces federal charges

Interim results of VITOBAâ„¢ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the …

ATLANTA, April 26, 2012 /PRNewswire/ -- UCB today announced interim results from the VITOBA (VImpaT added to One Baseline AED) study, which showed that patients with less refractory partial-onset seizures treated withVimpat (lacosamide) C-V as add-on to monotherapy experienced seizure reduction. These data were presented today at the 64th annual meeting of the American Academy of Neurology (AAN) in New Orleans.

VITOBA is a six-month prospective, non-interventional study of the efficacy, safety and tolerability of lacosamide when added to a single AED in patients with partial-onset seizures. The study has a planned enrollment of 500 adult patients. This interim analysis included efficacy data for 99 patients and safety data for 109 patients.

The patient population in VITOBA reflects epilepsy patients treated in routine clinical practice. The majority of patients (73.4 percent) had received only 1-3 AEDs since diagnosis. The mean lacosamide maintenance dose was 250mg/day and the median was 200mg/day.

Compared to the overall VITOBA study population, patients treated with only one lifetime AED experienced the greatest benefit from add-on therapy with lacosamide:

Treatment emergent adverse events (TEAEs) included fatigue (11.9 percent), dizziness (10.1 percent) and convulsion (5.5 percent).

"While preliminary, this interim analysis is noteworthy because it reflects a real-world treatment setting and suggests the effect of adding Vimpat as an adjunctive therapy after initial monotherapy. These results need to be confirmed by the final analysis when the study concludes," said Matthias Noack-Rink, lead study author and Medical Affairs Director, Epilepsy, UCB Germany.

Vimpat is indicated as an adjunctive therapy for the treatment of partial-onset seizures in adults with epilepsy. The most common adverse reactions reported in pivotal trials and occurring in 10 percent or more of lacosamide-treated patients, and greater than placebo, were dizziness, headache, nausea and diplopia. Additional important safety information for Vimpat is available at the end of the press release.

About EpilepsyEpilepsy is a chronic neurological disorder affecting approximately 50 million people worldwide and 3 million people in the U.S.Anyone can develop epilepsy; it occurs across all ages, races and genders. Uncontrolled seizures and medication side effects pose challenges to independent living, learning and employment, so the goal of epilepsy treatment is seizure freedom with minimal side effects. More than 1 million patients in the U.S. continue to have seizures despite initial therapy, and more than 800,000 patients in the U.S. continue to have seizures despite treatment with two or more therapies.[1],[2]

About VimpatVimpat tablets and injection were launched in the US in May 2009 as an add-on therapy for the treatment of partial-onset seizures in people with epilepsy who are aged 17 years and older. Vimpat injection is a short-term replacement when oral administration is not feasible in these patients. Vimpat oral solution was launched in June 2010. The availability of the oral tablets, oral solution, and IV injection allows for consistent treatment in a hospital setting. The most common adverse reactions occurring in greater than or equal to 10 percent of Vimpat -treated patients, and greater than placebo, were dizziness, headache, nausea and diplopia. Additional important safety information for Vimpat is available at the end of the press release.

In the European Union, Vimpat (film-coated tablets and solution for infusion) is approved as adjunctive therapy for the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy, aged 16 years and older. Vimpat solution for infusion may be used when oral administration is temporarily not feasible.

View post:
Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the ...

Man charged with leaving mercury in Albany Med cafeteria now facing federal charges

Martin Kimber

ALBANY The man already charged with putting mercury in food and on other places including the heater where it would be vaporized and inhaled in the Albany Medical Center Hospital cafeteria now faces federal charges.

U.S. Attorney Richard Hartunian said Martin S. Kimber, 58, of Ruby, faces charges of illegal disposal of a hazardous waste in a manner posing a danger of death of serious bodily injury to others, a charge more commonly referred to as knowing endangerment, and illegal storage and disposal of a hazardous waste without a permit.

The retired pharmacist was previously arrested by Albany Police, with help from FBI and Department of Health investigators, for tampering with a consumer product in the first degree.

According to the U.S. Attorneys Office, a search of Kimbers Ulster County home found he had 21 guns and literature reflecting a sympathy for domestic terrorism.

The cover page in one book, The Turner Diaries includes the phrase This book contains racist propaganda and The FBI said it was a blueprint for the Oklahoma City Bombing.

Investigators also discovered a Nazi swastika on the wall.

The knowing endangerment charge carries a 15 year maximum jail time and a fine of $250,000 or twice the gross loss to any victim. The storage and disposal of hazardous waste without a permit can lead to a maximum of five years in jail and a fine of $250,000 or twice the gross loss to any victim.

The mercury was found in some of the food in the cafeteria that was eaten by at least one person. That person was treated at the hospitals emergency room.

Excerpt from:
Man charged with leaving mercury in Albany Med cafeteria now facing federal charges

Cypress resident crowned Little Miss Wheelchair Texas

With her sparkling tiara, polka-dotted dress and beaming smile, 8-year-old Alana Little, a second grade student at Moore Elementary School, looks every bit a princess, although her fairy tale cant be found in storybooks.

Alana or simply Lana, as she is known by her family and friends was crowned Little Miss Wheelchair Texas 2012 on March 24 at the Crowne Plaza in Houston, selected by the Miss Wheelchair Texas Foundation for her inspiring story.

That night at the gala, Lana got a very long standing ovation for her story, said Teri Little, Lanas maternal grandmother, who has helped raise the young girl since she was 16 months old. Lanas been through a lot. Shes a tough cookie, that one.

As the result of an extremely rare genetic disorder, worsened by the effects of drug and alcohol exposure in utero, Lana was diagnosed with ataxia-telangiectasia, or A-T, at 23 months. The disease combines the worst symptoms of muscular dystrophy, cerebral palsy, cystic fibrosis and immune deficiencies.

Those with A-T are 1,000 times more likely to get cancer. There are an estimated 500 children in the U.S. living with A-T today, but this number is too small for pharmaceutical companies to conduct research for a cure.

It attacks the cerebellum, and Lanas cerebellum has been destroyed by the disease already. If we were to let Lana walk, she would more than likely fall down immediately or wobble like shes drunk, Terri said.

Lana has relied on a wheelchair for part-time mobility since she was 2, primarily to cope with the excessive fatigue that sends her to bed by 5:30 p.m. each day. She made the transition to full-time wheelchair dependence this past summer.

As Little Miss Wheelchair Texas, Lana will make public appearances at Texas Childrens Hospital, MD Anderson and a special needs program with the National Dance Institute. Her year-long service will serve as a means to bring light to children living with paralyzing diseases like A-T.

We were just so happy for her and happy we were going to be able to educate more people about the disease, said Elizabeth Casey, Lanas aunt and part-time aide.

As part of her term with the crown, Lana and her family have started the I Can, Just Watch Me initiative, which seeks to spread an empowering message about the abilities, rather than the disabilities, of children with special needs. Children are photographed with a sign of the slogan, and the images are shared online along with the childs name, age and diagnosis.

More:
Cypress resident crowned Little Miss Wheelchair Texas

Multiple Sclerosis Patients Find Improvement in Walking with BalanceWear®

OAKLAND, Calif.--(BUSINESS WIRE)--

The first phase of the NIH study, Movement Ability Changes with Balance-Based Torso-Weighting (BBTW) in Multiple Sclerosis (MS), provided important results for Multiple Sclerosis patients suffering with balance and walking challenges. The study is funded by a National Institutes of Health Recovery Grant that was awarded to Samuel Merritt University (SMU) Physical Therapy Professor Dr. Gail Widener, PT, and Dr. Diane Allen at San Francisco State University to continue research into Balance-Based Torso Weighting (BBTW) and its effects on Multiple Sclerosis (MS) mobility challenges. The first phase of the study validates previous research funded by the National MS Society.

Physical Therapist, Cynthia Gibson-Horn, discovered that strategic application of small amounts of weight could counter-balance directional losses and dramatically improve stability in patients with MS, Parkinsons disease, stroke, TBI ataxia and other Sensory Based Motor Disorders (SBMD) during clinical applications. This discovery led to the development of the patented BBTW method, which has now helped hundreds of patients. The NIH funded research provides documented evidence of the efficacy of her clinical observations.

The first phase of the NIH study supplements other research into BBTW, the technology behind BalanceWear, which has been highly successful in improving mobility for patients with MS, says Steve Cookston, CEO of Motion Therapeutics, the company that manufactures BalanceWear. I have joined Cindy in numerous treatment sessions and I am always inspired when I witness the immediate improvement in someone who has spent years struggling to manage daily activities due to poor balance. Its a wonderful experience.

Gibson-Horn acknowledges that each case is different regarding the degree of improvement that can be achieved after being strategically fitted with BalanceWear. Some patients walk nearly normally with BalanceWear, she says. We can see immediately upon application if a patients balance has been corrected. Further, we now know that the improved stability provided by BalanceWear is helpful in increasing confidence, which can lead to improved success in physical therapy often accelerating results.

Balance-Based Torso-Weighting is an assessment and treatment method that results in a BalanceWear custom made, strategically weighted orthotic. BalanceWear is made to the exact specifications for the patients counter-balancing requirements, providing supplementary sensory information to the nervous system, and helping to improve balance and stability in all directions of movement. Clinically, patients with the following conditions have found balance and mobility improvement with BalanceWear - Parkinsons disease, Multiple Sclerosis, stroke, head trauma, brain surgery, osteoporosis, ataxia, Cerebral Palsy and dizziness.

Dr. Gail Widener at Samuel Merritt University in Oakland, California and Dr. Diane Allen at San Francisco State University will present their research at the 64 Annual Academy of Neurology April 26th and at the Consortium Of MS Centers annual conference on June 1, 2012.

For more information on BalanceWear, visit http://www.motiontherapeutics.com. Motion Therapeutics is a provider of therapeutic products designed to improve balance, stability and mobility in many disease states utilizing patented Balance-Based Torso-Weighting (BBTW) technology available in the patented BalanceWear Series mobility products. The companys products are designed to: accelerate the recovery and rehabilitation of adults and children with balance challenges; and, improve the mobility, confidence, and independence of individuals. Visit MotionTherapeutics.com to learn more.

More:
Multiple Sclerosis Patients Find Improvement in Walking with BalanceWear®

An Autistic’s Response: “Teacher/Bully: How My Son Was Humiliated and Tormented by his Teacher” – Video

25-04-2012 16:38 This is my response to the video "Teacher/Bully: How My Son Was Humiliated and Tormented by his Teacher and Aide." To learn more check out the link here: My name is Kerry Magro and I was diagnosed with Autism at 4 and feel a great deal of compassion for Stuart and his 10 year old autistic son, Akian and there situation with The Cherry Hill School System. Please sign his petition here to help start a zero tolerance policy for teachers who bully their students: Join the Facebook Page "No More Teacher Bullies" here: Thanks to Stuart so much for making this public and sharing his voice with us! If you want to learn more about how I'm sharing my voice with others please check out my Blog here: my Homepage here: liking my Facebook Fan Page here: or following me on Twitter @kerrymagro Below I'm leaving you the description of what Stuart mentioned under his video description based on the situation with him and his son. For more information about the video please see below along with checking his Homepage here: "My name is Stuart Chaifetz, and my son, Akian, is a ten-year old boy who has Autism. Akian has always been a sweet and non-violent child, and that is why it was so distressing when notes started coming home from his school, Horace Mann Elementary in Cherry Hill, New Jersey, saying that he was having violent outbursts, including him hitting his teacher ...

Continue reading here:
An Autistic's Response: "Teacher/Bully: How My Son Was Humiliated and Tormented by his Teacher" - Video

An Autistic's Response: "Teacher/Bully: How My Son Was Humiliated and Tormented by his Teacher" – Video

25-04-2012 16:38 This is my response to the video "Teacher/Bully: How My Son Was Humiliated and Tormented by his Teacher and Aide." To learn more check out the link here: My name is Kerry Magro and I was diagnosed with Autism at 4 and feel a great deal of compassion for Stuart and his 10 year old autistic son, Akian and there situation with The Cherry Hill School System. Please sign his petition here to help start a zero tolerance policy for teachers who bully their students: Join the Facebook Page "No More Teacher Bullies" here: Thanks to Stuart so much for making this public and sharing his voice with us! If you want to learn more about how I'm sharing my voice with others please check out my Blog here: my Homepage here: liking my Facebook Fan Page here: or following me on Twitter @kerrymagro Below I'm leaving you the description of what Stuart mentioned under his video description based on the situation with him and his son. For more information about the video please see below along with checking his Homepage here: "My name is Stuart Chaifetz, and my son, Akian, is a ten-year old boy who has Autism. Akian has always been a sweet and non-violent child, and that is why it was so distressing when notes started coming home from his school, Horace Mann Elementary in Cherry Hill, New Jersey, saying that he was having violent outbursts, including him hitting his teacher ...

Continue reading here:
An Autistic's Response: "Teacher/Bully: How My Son Was Humiliated and Tormented by his Teacher" - Video

Experimental Drug Improves Autism-Like Symptoms in Mice

]ys6{)&5kMQ!y=G2lfR*$F~ uXc{Mlh Mb(}}fc?w0?iv"^L]<9(P6q}UWk{0KU,AaL*-PW{3/zJ]}5Z3C(]w:b`tl{=[5g2A;TL@(t:kO2S,9QC2t~ENL#|235w#VN#&G",#v4s**E0_Eh;ahz*K+0?2 MWa'JE(gC D'2*pg"HR6joC%Vyl3& cH'T&dUh2E1K<82fC.UD`/E]$<>*ix-x 70cW1SGLT6 H#S;wo eOf"rq6xFdb h]rlKB=:Dk4~#LOC `RO P _88x{0# '>km5y!1AtsJh-KfPFW@5Da& |0##F{IOme %WQ}/> / *>PB5H^kJkuV-%y}Y3%#T-CMP.EE 7%6V+{$4MGOItd{h+vk2_|4Bc.(8a.S/l6ez|-vsloUy_rL/_Znt`z*Ls=AjSfvb)7.+tr5.`Wc3T%'"I$T>,sR} n4Qun. "rf ( jp?,^f'`OHAt VK`r,<0@tH t=&a_Z$ow +qONY Q'#4X3o20X'CdF+$@!V4P"Si<8h4Su{{=h{Q{0#>@=RB=XN[HDRoO#k6{ux9'qQ<$06)|r&Z{H_ d$"q_h`NlJ m8s%yBB"5}=A(QoZUQ=i=c E=#o5%Llbz0 2X2p) N7i$y"N,S"A.)]l)>hNg6q=Av_Wc"^9wXtVS}]yqp3@1Gc8[,%&Q(#iuKu $fU*mxCr4PsCZ^(}nC"98Nd|%e%_ofxo4$Vk"I%/ ,q{S|z;zyJ1-}Hv )ECDjfR3oGY5Q@(Q(Yid*Ozw'C)sYe^cqHfS VOd|YOg+Qc4qW:TjfyY6/!jQ[fiT@vs[V{5MUJ>Oh-MXf T.u0_ m1EDE|sa>~yF |-g424Lv8Q[@_8aMFZF<|4M`OZVpEXf`h6`.XC4 Da5 ?[rz8& U$77G6>Y~IDHI`NUtj{T~ez^eqRn=Xy:H9EGFF4>41'V@xtHQ~~G }(G[@^F!QV>M"!-bM~f[|G~k#(wh"C~eoM3.-kbbeDZdeNk&^)?1a(PHA;EQZq?Oa1ZAKL6]F$$'<,o TFzD6$ydXA8 $r'4_] 6!@B 1 BP!;$JpB'e)~h Qbd?%>d9tTj1eR,=fI+Ti4U,`t4T`#ad|iaB|xA]'HZ4EknzC+4(M QQh8)>0,TL@1%^UmT0&kO#@+:_6&CC<#P,T_*UGOC"/$ Oa!4=iOI tgPD]1qF7(ZSb d]CtW9`CAco=knr;m!UtS]umfe_a=}b?;A.Nx<*$QchRR/VRGFdWfk&N^~x}f'MsQqjN-e h3+xLWplSEl3(D))b&O(XEZS-2Cn)TO#+2_fY>*~;_v{7~8 )s)o!%4C*.#5dUk.k:Fl}) :oMUqq8AU(K&0z&KhCbSP'_3CR "lmcwwoc!PTvZ/$O|vdUJ,+y|3{j!=}a+E"93bFwC(!vKcE x<2MU W@ni@-8z+rZ?xk&'B 02(#!~Az|0;re ~ih^/YY/VOP0]N%] I,+F,~YFW$iM9wCR48*uyF)U

Read the rest here:
Experimental Drug Improves Autism-Like Symptoms in Mice